GlycoErase™ ST6GAL2 Knockout Human Prostate Cancer Cell 22RV1 (CAT#: GLJF-0525-JF349)

Description	The ST6GAL2 knockout 22RV1 cell line enables the study of sialylation disruption in prostate cancer, potentially affecting sialylation of oligosaccharide substrates and sialic acid related pathways.
Product Type	KO Cell Lines
Species	Human
Cell Morphology	Epitheloid cells, adherent
Passage Ratio	1:3~1:10
Cell Line	22RV1
Primary Disease	Prostate Adenocarcinoma
Lineage	Prostate

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Culture Medium	DMEM & FBS & RPMI
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	ST6GAL2
Full Name	ST6 Beta-galactoside alpha-2,6-sialyltransferase 2
Alternative Name	SIAT2, KIAA1877, St6GalII
Location	2q12.3
Gene ID	84620
Summary	Sialyltransferase that modifies oligosaccharide substrates; polymorphisms may influence risperidone response in schizophrenia patients.